Get the Stockscreener App
0.91
7.31%
-0.0718
Pre-market:
.96
0.05
+5.49%
Opus Genetics Inc stock is traded at $0.91, with a volume of 224.68K.
It is down -7.31% in the last 24 hours and down -11.65% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$0.9818
Open:
$0.986
24h Volume:
224.68K
Relative Volume:
1.06
Market Cap:
$40.92M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-0.8349
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
-19.47%
1M Performance:
-11.65%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.886
$1.0002
1-Week Range:
$0.886
$1.13
52-Week Range:
$0.81
$1.56
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
0.91 | 40.92M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Opus Genetics price target lowered to $8 from $9 at JonesResearch - TipRanks
H.C. Wainwright maintains $8 target on Opus Genetics stock - Investing.com India
Opus Genetics Announces Full Year 2024 Financial Results, Provides Corporate Update - VisionMonday.com
Opus Genetics earnings missed by $1.22, revenue fell short of estimates - Investing.com Canada
Opus Leans Lower on Year-End Figures - Baystreet.ca
Opus Genetics Announces Financial Results for Full Year 2024 - TradingView
Ousted founder of drug development company tries to take back the reins - Crain's Detroit Business
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
Pleasing Signs As A Number Of Insiders Buy Opus Genetics Stock - simplywall.st
Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance
Opus Genetics closes $20M offering, issues private placement - Investing.com India
Opus Genetics closes $20M offering, issues private placement By Investing.com - Investing.com South Africa
Opus Genetics founder Mina Sooch files preliminary proxy materials for co board election - Marketscreener.com
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics - The Manila Times
Opus Genetics Prices Public Offering At $0.95/Share, Raising Over $20M - Nasdaq
Opus Genetics announces $21.5 million capital raise - Investing.com
Opus Genetics Prices Public Offering, Private Placement -March 21, 2025 at 09:33 am EDT - MarketScreener
Opus Genetics Announces Presentation on Phentolamine - GlobeNewswire
Opus Genetics announces $21.5 million capital raise By Investing.com - Investing.com Australia
1 Wall Street Analyst Thinks Tesla Will Hit $425. Is it a Buy Around $235? - The Globe and Mail
Opus Genetics, Inc. Announces $20 Million Public Offering and $1.5 Million Private Placement to Fund Clinical Development Initiatives - Nasdaq
Opus Genetics Announces Pricing of Public Offering and - GlobeNewswire
Opus Genetics Secures $21.5M Backing: Perceptive Advisors Leads Gene Therapy Push - Stock Titan
Opus Genetics reports $56.8 million loss for 2024 By Investing.com - Investing.com South Africa
Opus Genetics reports $56.8 million loss for 2024 - Investing.com
Form 424B5 Opus Genetics, Inc. - StreetInsider
Opus Genetics enhances shareholder rights, sues for patent infringement By Investing.com - Investing.com South Africa
Opus Genetics enhances shareholder rights, sues for patent infringement - Investing.com India
Opus Genetics grants stock options to new employees - Investing.com
Opus Genetics Approves Equity Awards for New Employees Under 2021 Inducement Plan - Nasdaq
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Examining the Potential Price Growth of TREX Co., Inc (TREX) - Knox Daily
Opus Genetics Strengthens Team with Strategic Stock Options Package for Key New Hires - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lumen21 Files Trademark Suit Over Rival's 2020 'Lumen' Rebrand - Bloomberg Law
US Space Force Can Proceed With $2.5 Billion Weapons Procurement - Bloomberg Law
Opus, Viatris Unit Sue Sandoz to Block Copy of Ryzumvi Eye Drug - Bloomberg Law
Disabled Applicant's Open-Book Exam Request Was Lawfully Denied - Bloomberg Law
1 Stock Under $50 with Exciting Potential and 2 to Ignore - The Globe and Mail
Trump Deportation Threats Draw Lawsuit From Cornell Students (1) - Bloomberg Law
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Pre-market Movers: AWH, TSVT, CUTR, SNOA... - RTTNews
Opus Genetics, Inc. Announces Acceptance of Three Abstracts for Presentation at ARVO 2025 Meeting - Nasdaq
Opus Genetics Announces Presentations at Association for - GlobeNewswire
Can Opus Genetics' Eye Disease Treatments Restore Vision? New Clinical Data Emerges - StockTitan
Opus Genetics faces patent challenge from Sandoz By Investing.com - Investing.com Australia
Opus Genetics faces patent challenge from Sandoz - Investing.com
Opus Genetics In Jan, Got Paragraph IV Certification Notice From Winston & Strawn, Counsel To Sandoz Incorporated - Marketscreener.com
Opus Genetics sets April 30 for 2025 Annual Meeting - MSN
Wells Fargo & Company Has Lowered Expectations for Westlake (NYSE:WLK) Stock Price - Defense World
Principal Financial Group Inc. Has $13.99 Million Stock Position in Stanley Black & Decker, Inc. (NYSE:SWK) - Defense World
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):